SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 17, 2012
PAR PHARMACEUTICAL COMPANIES, INC.
(Exact name of registrant as specified in its charter)
| | |
Delaware | File Number 1-10827 | 22-3122182 |
(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer |
incorporation or organization) |
| Identification No.) |
|
|
|
| |
300 Tice Boulevard, Woodcliff Lake, NJ | 07677 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (201) 802-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.07 Submission of Matters to a Vote of Security Holders
We held our annual stockholders’ meeting on May 17, 2012, at which a quorum was present. At the annual meeting, our stockholders (i) elected Peter S. Knight and Thomas P. Rice to serve as our Class I directors for a three-year term expiring at the 2015 annual meeting of stockholders, (ii) ratified Deloitte & Touche LLP as our independent registered public accounting firm for the 2012 fiscal year, (iii) approved our 2012 omnibus incentive plan as set forth in our Proxy Statement filed with the Securities and Exchange Commission on March 30, 2012, and (iv) approved the non-binding advisory vote on our 2011 executive compensation programs and policies for our Named Executives (as described in the Compensation Discussion and Analysis set forth in our Proxy Statement).
The following are the voting results for these proposals:
PROPOSAL 1 – Election of Class I directors for a three-year term expiring at the 2015 annual meeting of stockholders:
| | | |
| For | Withheld | Broker Non-Votes |
|
|
|
|
Peter S. Knight | 29,969,702 | 1,310,633 | 2,433,458 |
Thomas P. Rice | 30,236,627 | 1,043,708 | 2,433,458 |
PROPOSAL 2 – Ratification of Deloitte & Touche LLP as our independent registered public accounting firm for 2012:
| | | |
For | Against | Abstain | Broker Non-Votes |
|
|
|
|
33,296,412 | 406,243 | 11,138 | 0 |
PROPOSAL 3 – Approval of our 2012 Omnibus Incentive Plan:
| | | |
For | Against | Abstain | Broker Non-Votes |
|
|
|
|
22,046,742 | 9,207,571 | 26,022 | 2,433,458 |
PROPOSAL 4 – Non-binding advisory vote on our 2011 executive compensation programs and policies for our Named Executives:
| | | |
For | Against | Abstain | Broker Non-Votes |
|
|
|
|
26,560,126 | 4,442,996 | 277,213 | 2,433,458 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated as of: May 21, 2012
PAR PHARMACEUTICAL COMPANIES, INC.
(Registrant)
/s/ Thomas J. Haughey
Thomas J. Haughey, President
3
